Mario E. Lacouture, MD, discusses the psychosocial impact of dermatologic adverse events from novel therapies in melanoma.
Mario E. Lacouture, MD, dermatologist, Memorial Sloan Kettering Cancer Center, discusses the psychosocial impact of dermatologic adverse events from novel therapies in melanoma.
This impact has been demonstrated in questionnaires from several studies. Lacouture says he has encountered patients who are not willing to go to work because they do not want to disclose that an acneiform rash is from treatment for melanoma. Lacouture has also seen patients who have been unable to sleep because of rash or pruritus.
Finally, he says that both physicians and nurses need to focus on helping their patients live better as well as longer.
Apalutamide/ADT Confers 100% Recurrence-Free Survival in High-Risk Prostate Cancer
TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer
UGN-102 Produces Comparable Responses Regardless of Surgery in NMIBC Subset
Verbal Workflow for Tocilizumab Orders Results in More Timely CRS Intervention
2 Commerce Drive
Cranbury, NJ 08512